Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation (START)

  • STATUS
    Recruiting
  • End date
    Dec 8, 2023
  • participants needed
    1000
  • sponsor
    University of Texas at Austin
Updated on 8 June 2022
anticoagulants
atrial fibrillation
thrombolytic
rivaroxaban
ischemic stroke
deficit

Summary

Title

Optimal Delay Time to Initiate Anticoagulation after Ischemic Stroke in Atrial Fibrillation (START): a pragmatic, adaptive randomized clinical trial.

Primary Objective:

• To determine the optimal time to initiate anticoagulation with a Non-Vitamin K Oral Anticoagulant (NOAC) after ischemic stroke in patients with non-valvular atrial fibrillation.

Secondary Objectives:

  • To compare the rates of primary adverse outcomes in a per protocol analysis
  • To compare 30 day clinical outcomes by the modified Rankin scale among the time-to-treatment groups
  • To compare 30 day clinical outcomes by the PROMIS-10 scale among the time-to-treatment groups.
  • To compare 90 day clinical outcomes by the modified Rankin scale among the time-to-treatment groups
  • To explore the optimal timing in subgroups of age, sex, outcome category, and NOAC choice

Description

Long-term oral anticoagulation is standard for secondary stroke prevention in patients with atrial fibrillation (AFib). However, there is limited data and no consensus on the timing of when to initiate anticoagulation therapy, and concern that starting too soon risks symptomatic hemorrhagic transformation. These data are derived almost exclusively from heparins and Vitamin K antagonists (e.g.,warfarin). Now that NOACs have become the mainstay of stroke prophylaxis in AFib and have more rapid and consistent anticoagulation and fewer strokes (hemorrhagic especially), the question of optimal timing of NOAC initiation is of increasing importance.

The primary aim is to determine the time-to-treatment interval with the lowest associated risk for adverse events in the context of anticoagulation therapy with NOACs for acute stroke patients with non-valvular AFib. The question will be investigated with a prospective, adaptive, randomized, controlled "dose-exploration" trial with the time to treatment with NOAC therapy treated as the incremental "dose".

An adaptive, pragmatic trial will be performed that will not deviate from the treating physicians' usual practice except for randomizing the time to start the NOAC. Data collection will be limited to those fields necessary for the planned primary and secondary analyses.

The composite primary outcome event will be any of the following within 30 days of the index stroke: Ischemic Events (symptomatic ischemic stroke or systemic embolism), Hemorrhagic Events (symptomatic hemorrhagic transformation of index ischemic stroke, other symptomatic intracranial hemorrhage, or major extracranial hemorrhage), or all-cause mortality.

Four time-to-treatment intervals, i.e. study arms, between 2 and 14 days will be investigated: 60 hours, 132 hours, 228 hours, and 324 hours. An innovative adaptive design will be used which includes response adaptive randomization and modeling of ischemic and hemorrhagic outcome events. The ischemic and hemorrhagic events within the composite primary endpoint are modeled separately using their known monotonic property that the risk of an event increases (ischemic) or decreases (hemorrhage) as the time-to-treatment interval lengthens. Interim analyses will occur after every 100 subjects are randomized, where the primary outcome will be analyzed and new randomization probabilities will be calculated to favor the arms that have a better risk-profile.

Details
Condition Stroke
Treatment Time-To-Treatment Randomization
Clinical Study IdentifierNCT03021928
SponsorUniversity of Texas at Austin
Last Modified on8 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

New disabling neurological deficit attributable to new ischemic stroke
Minimum lesion diameter of 1.5cm on qualifying imaging. If lesion not visible on imaging, NIHSS must be greater than 4
Non-valvular atrial fibrillation (paroxysmal, persistent, or permanent)
Not currently anticoagulated and/or will not be anticoagulated prior to starting their NOAC at the randomized time of initiation (except for DVT prophylaxis)
Note: Patients who had been taking an anticoagulant prior to their qualifying
index event (for any reason) are eligible for START, assuming the drug is no
longer having a therapeutic effect in the patient's system by 48 hours from
stroke onset
Treating physician plans to anticoagulate with a FDA-approved novel oral anticoagulant (NOAC): apixaban, dabigatran, edoxaban, or rivaroxaban, or other FDA-approved NOAC
Qualifying brain CT or MRI scan < 48hr from stroke onset (time last known well). If patient has been treated with thrombolytic or endovascular therapy for this stroke, then the qualifying scan is that which is performed after therapy to rule out clinically significant hemorrhagic transformation
Ability to randomize within 60 hours of symptom onset

Exclusion Criteria

cerebral microbleed is considered to be ≤ 5mm, but sometimes up to 10mm, in
Any clinical or imaging evidence of spontaneous intracranial hemorrhage in the previous 6 months
Note: Patients with hemorrhagic transformation of current or previous ischemic
Infarct volume (estimated) is greater than 50% of middle cerebral artery territory on qualifying scan. If the full extent of the lesion is not visible, any patient with a NIHSS > 23 must be excluded
stroke may be included per Investigator's judgment. Sporadic microbleeds may
be included per Investigator's judgment. As a general recommendation, a
greatest diameter on gradient recalled echo (GRE), or T2, MRI sequences. Any
blood visualized on a CT will be classified as a macrobleed
Note: The lesion does not need to be restricted to the mCA, but if the lesion
volume is estimated to be greater than half of the mCA territory, the patient
Anticipated need for major surgery over the next 30 days that would require delay, discontinuation, or extended suspension of anticoagulant of more than 5 days
should be excluded
Symptomatic edema expected from size and location of ischemic stroke
Note: In non-EVT patients, any NIHSS following the index stroke may be used to
Decreased level of consciousness present or expected
qualify the patient for START. For example, a patient that presents with a
Life expectancy less than 90 days
NIHSS of 10 who then receives tPA and improves to a NIHSS of 2 is still
Follow-up in person or by telephone for 90 days is not feasible
eligible for START. For patients whom had endovascular therapy, the qualifying
NIHSS assessment is that which is obtained with their qualifying scan
following therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note